SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing high volatility as investors weigh contradictory reports and government statements regarding the potential end of the conflict in Iran. While some traders are betting on a sharp reversal based on reports of diplomatic negotiations and ceasefire talk, others remain bullish on the energy sector, citing the continued closure of the Strait of Hormuz and structural supply risks.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is trending due to significant market volatility driven by conflicting signals regarding the ongoing Middle East conflict and upcoming official government announcements. Community discourse is currently split between optimism over potential de-escalation catalysts and skepticism regarding institutional market manipulation and long-term geopolitical stability.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike shares are facing significant downward pressure following disappointing guidance and persistent concerns over international growth, prompting a heated debate among investors regarding the company's long-term turnaround potential. While some community members view the decline as a generational buying opportunity and note recent insider stake-building, others argue the brand is losing relevance to competitors and remain skeptical of management's ability to navigate current headwinds.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC remains at the center of investor focus as massive institutional call-side activity and sustained demand for advanced AI hardware bolster sentiment, despite ongoing supply chain constraints and geopolitical risks. The market is actively weighing the stock's role as the indispensable foundry for AI silicon against macro-level pressures and evolving semiconductor sector dynamics.

Ganymede

Ganymede is capturing attention through steady price action and clean accumulation patterns that have the community feeling confident in the asset's structural integrity. Investors are actively discussing the potential for a breakout, characterized by disciplined buying pressure and a lack of forced volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing significant downward pressure as market sentiment sours amid fresh antitrust concerns, legal losses regarding user safety, and mounting investor anxiety over the immense capital expenditure required for AI infrastructure. Community discourse remains deeply divided between those calling for a technical breakdown toward key support levels and bargain hunters betting that current price levels offer a long-term entry point for a dominant market leader.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is surging as investors react to a wave of positive catalysts, including upcoming delivery reports and a significant production milestone for the ES8, while the community debates the stock's long-term valuation versus immediate short-term volatility. Enthusiastic investors are focusing on the company's expansion into new markets and model upgrades, hoping these moves will fuel a sustained rebound and trigger a short squeeze.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp is currently under the spotlight as investors debate the impact of pending project updates, including a replacement Definitive Feasibility Study (DFS) and a potential shift in project valuation. The community remains sharply divided between those accumulating shares on dips in anticipation of long-term supply chain demand and those voicing skepticism regarding management's transparency and historical project projections.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant investor attention following a strong earnings report and the announcement of a major order for Airbus A350F engines, fueling bullish sentiment among long-term shareholders. The community is actively discussing the stock's resilience, its strategic positioning in the SMR and defense sectors, and the company's aggressive share buyback program despite broader geopolitical uncertainty.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy Co. is surging due to investor speculation surrounding its Arctic exploration drilling agreement and potential to unlock vast oil reserves. The community remains highly active, debating the stock's speculative upside versus concerns over its status as a recent SPAC listing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.</li><li>Early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events, the company said.</li><li>Traws is advancing Tivoxavir Marboxil as a potential once-monthly oral preventive treatment for seasonal flu.</li></ul>Shares of Traws Pharma, Inc. (TRAW) gained about 5% in premarket trading but slipped after the opening bell following the company’s announcement that it has completed enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer, used to treat mild-to-moderate COVID-19. Traws said that patients unable to take Paxlovid are often at greater risk of severe disease, and that Ratutrelvir may help address this unmet need as an alternative treatment option.Patients receiving Ratutrelvir were treated with a once-daily oral dose for 10 days, while those in the separate treatment arm received standard Paxlovid dosing for five days. According to the company, early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events.“The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that Ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID),” said Robert R. Redfield, Chief Medical Officer of Traws Pharma.<h2 class="st-heading-2">Influenza Treatment Update</h2>In addition to the COVID-19 program, Traws provided an update on Tivoxavir Marboxil, an investigational antiviral for influenza. The company is advancing the drug as a potential once-monthly oral preventive treatment for seasonal flu, expanding its pipeline of therapies targeting respiratory viral diseases.Meanwhile,&nbsp;retail sentiment for TRAW remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/TRAW_jpg_41217ff328.webp" alt="TRAW.jpg">The stock has rebounded sharply in 2026, with <a href="https://stocktwits.com/symbol/TRAW">TRAW</a> up more than 115% amid renewed buying interest.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mnkd-stock-jump-over-7-in-pre-market-today/cmy787FR4Wz">Why Did MNKD Stock Jump Over 7% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Equity

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$1.83
Prev Close	$1.75
Open	$1.81
Dividend Yield	N/A
50-Day Moving Average	$1.97
Beta	1.26
Avg. Volume	140,118.50
PE Ratio	0.08

52-Week High	$3.27
52-Week Low	$0.97
Market Capitalization	$13.98M
EPS (Annual)	N/A
Price to Book	2.87
Revenue Per Employee	N/A

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRAW News

TRAWTraws Pharma Inc.